Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine (CoronaVac) co-administered with an inactivated quadrivalent influenza vaccine: A randomized,open-label,controlled study in healthy adults aged 18 to 59 years in China |
| |
Institution: | 1. Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, Zhejiang Province, China;2. Sinovac Biotech CO., Ltd., Beijing 100085, China;3. Kaihua County Center for Disease Control and Prevention, Quzhou 324300, Zhejiang Province, China;4. School of Public Health, Xiamen University, Xiamen 361102, Fujian Province, China |
| |
Abstract: | BackgroundStudies are needed for evidence of inactivated COVID-19 vaccine co-administered with influenza vaccine.MethodsA randomized, open-label, controlled study was conducted in Zhejiang Province, China. Eligible healthy adults aged 18–59 years underwent randomization at a ratio of 1:1:2 to receive inactivated quadrivalent influenza vaccine (IIV4) either concomitantly with the first (C1 subgroup) or the second (C2 subgroup) dose of CoronaVac, or 14 days after the first dose of CoronaVac (S group). The primary purpose of the study was to prove the non-inferiority in seroconversion rate of antibody against SARS-CoV-2.ResultsOverall, 480 participants were enrolled, with 120, 120, and 240 randomly assigned to the C1, C2, and S groups, respectively. As lower bound of the two-sided 95% confidence interval (CI) of the difference for the seroconversion rate of antibodies against SARS-CoV-2 was over ?10%, the immune response for CoronaVac in the C group (93.1% 89.0, 96.0]) was non-inferior to that in the S group (95.2% 91.5, 97.6]) in the per-protocol set. A lower GMT of antibody against SARS-CoV-2 was observed in the C group as compared to the S group (27.5 vs. 38.1, P = 0.0001). Decrease of immune response to CoronaVac was mainly observed in participants received IIV4 concomitantly with their second dose of CoronaVac (C2 subgroup), with a seroconversion rate of 89.7% (95CI: 82.6%-94.5%) and a GMT of 23.3. The occurrences of vaccine related adverse reactions were no more than 20% and comparable among different groups. Most of the adverse reactions were mild and moderate.ConclusionCo-administration of inactivated COVID-19 vaccine and seasonal influenza vaccine, especially the administration regimen that the seasonal influenza vaccine co-administered with the first dose of the inactivated COVID-19 vaccine, would be feasible. |
| |
Keywords: | SARS-CoV-2 COVID-19 vaccine Concomitant administration Influenza vaccine SARS-CoV-2"} {"#name":"keyword" "$":{"id":"pc_bzpTtDq5ic"} "$$":[{"#name":"text" "_":"severe acute respiratory syndrome coronavirus 2 COVID-19"} {"#name":"keyword" "$":{"id":"pc_dnMifh9573"} "$$":[{"#name":"text" "_":"Corona Virus Disease 2019 IIV4"} {"#name":"keyword" "$":{"id":"pc_1qJlWazk3H"} "$$":[{"#name":"text" "_":"inactivated quadrivalent influenza vaccine ZJCDC"} {"#name":"keyword" "$":{"id":"pc_GNWthicLzi"} "$$":[{"#name":"text" "_":"Zhejiang Provincial Center for Disease Control and Prevention AE"} {"#name":"keyword" "$":{"id":"pc_iAeOHHalfy"} "$$":[{"#name":"text" "_":"adverse event SAE"} {"#name":"keyword" "$":{"id":"pc_FUx09fF6T4"} "$$":[{"#name":"text" "_":"seriousadverse event AR"} {"#name":"keyword" "$":{"id":"pc_kiwHYtnDEH"} "$$":[{"#name":"text" "_":"advers reaction GMT"} {"#name":"keyword" "$":{"id":"pc_NJvr2TNuNN"} "$$":[{"#name":"text" "_":"geometric mean titer GMI"} {"#name":"keyword" "$":{"id":"pc_ldbzyb4Hdw"} "$$":[{"#name":"text" "_":"geometric mean increase SS"} {"#name":"keyword" "$":{"id":"pc_HNSHFe1eDD"} "$$":[{"#name":"text" "_":"safety analysis set CI"} {"#name":"keyword" "$":{"id":"pc_0fcHyWV8Lx"} "$$":[{"#name":"text" "_":"confidence interval |
本文献已被 ScienceDirect 等数据库收录! |
|